Login / Signup

Impact of baseline body mass index on the efficacy and safety of tofacitinib in patients with psoriatic arthritis.

Jon T GilesAlexis OgdieJuan J Gomez ReinoPhilip S HelliwellRebecca GerminoLori StockertPamela YoungWael JosephRajiv MundayatDaniela GrahamChristopher T Ritchlin
Published in: RMD open (2021)
Tofacitinib demonstrated greater efficacy than placebo in patients with PsA, regardless of baseline BMI. For all treatment arms, reduced efficacy was observed in patients with baseline BMI ≥35 kg/m2. Safety was generally comparable across BMI categories, although the effect of tofacitinib on liver enzymes in patients with baseline BMI ≥35 kg/m2 was inconclusive.
Keyphrases
  • body mass index
  • weight gain
  • rheumatoid arthritis
  • ulcerative colitis
  • physical activity
  • clinical trial
  • randomized controlled trial
  • weight loss
  • double blind
  • radical prostatectomy